Antituberculosis Drug-Associated DRESS: A Case Series

Journal of Allergy and Clinical Immunology: in Practice 6, 1373-1380 DOI: 10.1016/j.jaip.2017.11.021

Citation Report

#	Article	IF	CITATIONS
1	Dolutegravir as a trigger for DRESS syndrome?. International Journal of STD and AIDS, 2018, 29, 1036-1038.	0.5	5
2	Ethambutol/pyrazinamide/rifampicin. Reactions Weekly, 2018, 1711, 119-119.	0.0	0
3	Recent developments and highlights in drug hypersensitivity. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2368-2381.	2.7	49
4	Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome Associated with Ethambutol use: A Case Report. Current Drug Safety, 2019, 14, 249-251.	0.3	2
5	The Journal of Allergy and Clinical Immunology: In Practice 2018 Highlights. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 393-411.	2.0	5
6	Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome caused by firstâ€ŀine antituberculosis drugs: Two case reports and a review of the literature. Contact Dermatitis, 2019, 81, 325-331.	0.8	15
8	Prevalence and Clinical Features of Drug Reactions With Eosinophilia and Systemic Symptoms Syndrome Caused by Antituberculosis Drugs: A Retrospective Cohort Study. Allergy, Asthma and Immunology Research, 2019, 11, 90.	1.1	19
9	Mixed lichenoid and psoriasiform drug eruption induced by rifampicin. Australasian Journal of Dermatology, 2020, 61, e231-e233.	0.4	3
10	Hypersensibilités retardées aux antituberculeux. Revue Francaise D'allergologie, 2020, 60, 248-249.	0.1	0
11	Antibacterial antibiotic-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a literature review. European Journal of Clinical Pharmacology, 2021, 77, 275-289.	0.8	49
12	Severe Cutaneous Adverse Reactions Caused by Anti-Tubercular Drugs. Allergy, Asthma and Immunology Research, 2021, 13, 173.	1.1	0
13	Actualización en el tratamiento de las reacciones adversas cutáneas graves a los medicamentos. Revista De La Asociación Colombiana De DermatologÃa Y CirugÃa Dermatológica, 2021, 28, 340-351.	0.0	0
14	Severe Cutaneous Adverse Reactions to Anti-tuberculosis Drugs in Korean Patients. Allergy, Asthma and Immunology Research, 2021, 13, 245.	1.1	13
15	Hypersensitivity Reactions to Non-Beta Lactam Antibiotics. Current Treatment Options in Allergy, 2021, 8, 161-193.	0.9	1
16	Reintroduction of Antituberculous Drugs in Patients with Antituberculous Drug-Related Drug Reaction with Eosinophilia and Systemic Symptoms. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3442-3449.e3.	2.0	11
17	Hypersensitivity Myocarditis Due to Antitubercular Drugs in Children. Pediatric Infectious Disease Journal, 2020, 39, 1088-1091.	1.1	2
18	DiHS/DRESS syndrome induced by second-line treatment for tuberculosis and Epstein-Barr virus. Central-European Journal of Immunology, 2021, 46, 401-404.	0.4	1
19	Antituberculosis induced drug reaction with eosinophilia and systemic symptoms in a pediatric latent tuberculosis infection overdiagnosed as tuberculosis disease. , 2020, , 304-310.		0

CITATION REPORT

#	Article	IF	CITATIONS
20	Antiviral Induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Dyndrome: A Literature Review. Journal of Pharmaceutical Care, 0, , .	0.0	0
21	Patch testing in drug reaction with eosinophilia and systemic symptoms (<scp>DRESS</scp>): A literature review. Contact Dermatitis, 2022, 86, 443-479.	0.8	13
22	Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS)/Drug-Induced Hypersensitivity Syndrome (DiHS)—Readdressing the DReSS. Biomedicines, 2022, 10, 999.	1.4	16
23	DRESS syndrome due to first-line antitubercular therapy – A diagnostic imbroglio!. Journal of Family Medicine and Primary Care, 2022, 11, 3280.	0.3	1
24	Management of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome in a female Indonesian with pulmonary tuberculosis: A rare case report. Annals of Medicine and Surgery, 2022, 81,	0.5	2
25	ATT associated DRESS syndrome in a patient of multidrug resistant tuberculosis diagnosed on lymph node FNAC. Indian Journal of Pathology and Oncology, 2022, 9, 364-366.	0.1	0
26	Successful management with ganciclovir of drug reaction with eosinophilia and systemic symptoms secondary to antituberculous drugs associated to human herpesvirus-6 reactivation. JAAD Case Reports, 2023, 34, 90-93.	0.4	2